About Vico
Vico is a company based in Leiden (Netherlands) founded in 2019 by Judith Van Deutekom and Gail Mandel. Vico has raised $103.3 million across 3 funding rounds from investors including EQT, Eurazeo and Idinvest Partners. Vico offers products and services including VO659 and ASO Platform. Vico operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
- Headquarter Leiden, Netherlands
- Founders Judith Van Deutekom, Gail Mandel
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Vico Therapeutics B.V.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$103.3 M (USD)
in 3 rounds
-
Latest Funding Round
$12.3 M (USD), Series B
Jun 24, 2024
-
Investors
EQT
& 10 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Vico
Vico offers a comprehensive portfolio of products and services, including VO659 and ASO Platform.
Targets CAG repeat expansion to reduce mutant proteins in neurological diseases.
Enables precision targeting of genetic mutations for rare disorders.
People of Vico
Unlock access to complete
Unlock access to complete
Funding Insights of Vico
Vico has successfully raised a total of $103.3M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $12.3 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Vico
Vico has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include EQT, Eurazeo and Idinvest Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seroba Lifesciences is focused on life sciences venture capital investments.
|
Locked | Locked | Locked | |
|
Biotech startups are funded through venture capital in life sciences.
|
Locked | Locked | Locked | |
|
Droia Ventures is focused on investing in drug development companies.
|
Locked | Locked | Locked |
Investor details for Vico
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Vico
Investment portfolio details for Vico
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Vico
Detailed financials for Vico
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Vico Comparisons
Peer comparison for Vico
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Vico
Vico operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
Detailed competitors of Vico
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Vico
Complete news archive for Vico
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vico
Vico was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Vico is headquartered in Leiden, Netherlands. It is registered at Leiden, South Holland, Netherlands.
Vico is a funded company, having raised a total of $103.3M across 3 funding rounds to date.
Vico was founded in 2019 in Leiden, Netherlands, within the biotechnology sector. Antisense oligonucleotide therapies are designed using the VICOMER platform to target RNA in genetic neurological disorders. Conditions addressed include Rett syndrome, Alzheimers disease, Huntingtons disease, and others. The lead program, VO659, is advanced for polyglutamine-related diseases such as spinocerebellar ataxia types 3 and 1, along with Huntingtons disease. Operations focus on therapeutic development for unmet needs in neurology.
Vico's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
Vico offers VO659 and ASO Platform.
Vico has 11 investors. Key investors include EQT, Eurazeo, Idinvest Partners, Kurma Partners, and Ackermans & van Haaren.